Premium
A commercialized dietary supplement alleviates joint pain in community adults: a double‐blind, placebo‐controlled community trial (245.8)
Author(s) -
Nieman David,
Shanely R. Andrew,
Luo Beibei,
Dew Dustin,
Meaney Mary Pat,
Sha Wei
Publication year - 2014
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.28.1_supplement.245.8
Subject(s) - medicine , placebo , osteoarthritis , womac , joint pain , physical therapy , randomized controlled trial , alternative medicine , pathology
Instaflex TM is a joint pain supplement containing glucosamine sulfate, methylsufonlylmethane (MSM), white willow bark extract (standardized to 15% salicin), ginger root concentrate, boswella serrata extract (standardized to 65% boswellic acid), turmeric root extract, cayenne, and hyaluronic acid. Subjects included 100 men and women, ages 50‐75 years, with a history (>3 months) of joint pain, and were randomized to Instaflex or placebo (3 colored gel capsules per day for 8 weeks, double‐blind administration). Joint pain severity was significantly reduced in Instaflex compared to placebo (8‐week WOMAC, ‐37% versus ‐16%, respectively, interaction effect P=0.025), with group differences emerging by week 4. Improvements in ability to perform daily activities and stiffness scores in Instaflex were most evident for the 74% of subjects reporting knee pain (8‐week WOMAC function score, ‐39% versus ‐14%, respectively, interaction effect P=0.027; stiffness score, ‐30% versus ‐12%, respectively, interaction effect P=0.081). Patterns of change in SF‐36, systemic inflammation biomarkers, and the 6‐minute walk test did not differ significantly between groups. Results from this randomized, double blind, placebo‐controlled community trial support the use of the Instaflex dietary supplement in alleviating joint pain severity in middle‐aged and older adults.